SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Noad R., Roy P. (2003) Virus-like particles as immunogens. Trends Microbiol 11: 43844.
  • 2
    Jennings G.T., Bachmann M.F. (2008) The coming of age of virus-like particle vaccines. Biol Chem 389: 52136.
  • 3
    Grgacic E.V., Anderson D.A. (2006) Virus-like particles: passport to immune recognition. Methods 40: 605.
  • 4
    Spohn G., Bachmann M.F. (2008) Exploiting viral properties for the rational design of modern vaccines. Expert Rev Vaccines 7: 4354.
  • 5
    Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D.L., Kitchener H.C., Castellsague X., De Carvalho N.S., Skinner S.R., Harper D.M., Hedrick J.A., Jaisamrarn U., Limson G.A., Dionne M., Quint W., Spiessens B., Peeters P., Struyf F., Wieting S.L., Lehtinen M.O., Dubin G. (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369: 216170.
  • 6
    Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., Tang G.W., Ferris D.G., Steben M., Bryan J., Taddeo F.J., Railkar R., Esser M.T., Sings H.L., Nelson M., Boslego J., Sattler C., Barr E., Koutsky L.A. (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356: 192843.
  • 7
    Garcon N., Chomez P., Van Mechelen M. (2007) GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 6: 72339.
  • 8
    Mond J.J., Seghal E., Kung J., Finkelman F.D. (1981) Increased expression of I-region-associated antigen (Ia) on B cells after cross-linking of surface immunoglobulin. J Immunol 127: 8818.
  • 9
    Monroe J.G., Cambier J.C. (1983) B cell activation. II. Receptor cross-linking by thymus-independent and thymus-dependent antigens induces a rapid decrease in the plasma membrane potential of antigen-binding B lymphocytes. J Immunol 131: 26414.
  • 10
    Cheng P.C., Dykstra M.L., Mitchell R.N., Pierce S.K. (1999) A role for lipid rafts in B cell antigen receptor signaling and antigen targeting. J Exp Med 190: 154960.
  • 11
    Clark M.R., Massenburg D., Zhang M., Siemasko K. (2003) Molecular mechanisms of B cell antigen receptor trafficking. Ann N Y Acad Sci 987: 2637.
  • 12
    Kakiuchi T., Chesnut R.W., Grey H.M. (1983) B cells as antigen-presenting cells: the requirement for B cell activation. J Immunol 131: 10914.
  • 13
    Wang L.D., Clark M.R. (2003) B-cell antigen-receptor signalling in lymphocyte development. Immunology 110: 41120.
  • 14
    Scandella E., Fink K., Junt T., Senn B.M., Lattmann E., Forster R., Hengartner H., Ludewig B. (2007) Dendritic cell-independent B cell activation during acute virus infection: a role for early CCR7-driven B-T helper cell collaboration. J Immunol 178: 146876.
  • 15
    Reddy S.T., Rehor A., Schmoekel H.G., Hubbell J.A., Swartz M.A. (2006) In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release 112: 2634.
  • 16
    Tsutsui Y., Tomizawa K., Nagita M., Michiue H., Nishiki T., Ohmori I., Seno M., Matsui H. (2007) Development of bionanocapsules targeting brain tumors. J Control Release 122: 15964.
  • 17
    Kurata N., Shishido T., Muraoka M., Tanaka T., Ogino C., Fukuda H., Kondo A. (2008) Specific protein delivery to target cells by antibody-displaying bionanocapsules. J Biochem (Tokyo) 144: 7017.
  • 18
    Wu S.C., Yu C.H., Lin C.W., Chu I.M. (2003) The domain III fragment of Japanese encephalitis virus envelope protein: mouse immunogenicity and liposome adjuvanticity. Vaccine 21: 251622.
  • 19
    Alka B.K., Malik Y.P., Vrati S. (2007) Immunogenicity and protective efficacy of the E. coli-expressed domain III of Japanese encephalitis virus envelope protein in mice. Med Microbiol Immunol 196: 22731.
  • 20
    Verma S.K., Kumar S., Gupta N., Vedi S., Bhattacharya S.M., Lakshmana Rao P.V. (2009) Bacterially expressed recombinant envelope protein domain III of Japanese encephalitis virus (rJEV-DIII) elicits Th1 type of immune response in BALB/c mice. Vaccine 27: 69059.
  • 21
    Tafuku S., Miyata T., Tadano M., Mitsumata R., Kawakami H., Harakuni T., Sewaki T., Arakawa T. (2012) Japanese encephalitis virus structural and nonstructural proteins expressed in Escherichia coli induce protective immunity in mice. Microbes Infect Inst Pasteur 14: 16976.
  • 22
    Kuroda S., Otaka S., Miyazaki T., Nakao M., Fujisawa Y. (1992) Hepatitis B virus envelope L protein particles. Synthesis and assembly in Saccharomyces cerevisiae, purification and characterization. J Biol Chem 267: 195361.
  • 23
    Yamada T., Iwabuki H., Kanno T., Tanaka H., Kawai T., Fukuda H., Kondo A., Seno M., Tanizawa K., Kuroda S. (2001) Physicochemical and immunological characterization of hepatitis B virus envelope particles exclusively consisting of the entire L (pre-S1 + pre-S2 + S) protein. Vaccine 19: 315463.
  • 24
    Miyata T., Harakuni T., Tsuboi T., Sattabongkot J., Ikehara A., Tachibana M., Torii M., Matsuzaki G., Arakawa T. (2011) Tricomponent immunopotentiating system as a novel molecular design strategy for malaria vaccine development. Infect Immun 79: 426075.
  • 25
    Matsuo T., Yoshimoto N., Iijima M., Niimi T., Jung J., Jeong H.S., Choi E.K., Sewaki T., Arakawa T., Kuroda S. (2012) Engineered hepatitis B virus surface antigen L protein particles for in vivo active targeting of splenic dendritic cells. Int J Nanomed 7: 334150.
  • 26
    Arakawa T. (2011) Adjuvants: no longer a “dirty little secret”, but essential key players in vaccines of the future. Expert Rev Vaccines 10: 15.
  • 27
    Iijima M., Kadoya H., Hatahira S., Hiramatsu S., Jung G., Martin A., Quinn J., Jung J., Jeong S.Y., Choi E.K., Arakawa T., Hinako F., Kusunoki M., Yoshimoto N., Niimi T., Tanizawa K., Kuroda S. (2011) Nanocapsules incorporating IgG Fc-binding domain derived from Staphylococcus aureus protein A for displaying IgGs on immunosensor chips. Biomaterials 32: 145564.
  • 28
    Rosenberg A.S. (2006) Effects of protein aggregates: an immunologic perspective. AAPS J 8: E5017.
  • 29
    Bachmann M.F., Rohrer U.H., Kundig T.M., Burki K., Hengartner H., Zinkernagel R.M. (1993) The influence of antigen organization on B cell responsiveness. Science 262: 144851.
  • 30
    Bachmann M.F., Hengartner H., Zinkernagel R.M. (1995) T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction? Eur J Immunol 25: 344551.